Wechselwirkungen · Ifirmacombi
Ifirmacombi 150 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-125145 · Präparat HOS-096013
Medicinal products affecting potassium: The potassium-depleting effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide on serum potassium would be expected to be potentiated by other medicinal products associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-16T11:57:00Z · SHA-256 de9ed4436066d5e17ee66d54836788a39065e3bc0f0ec088c02563c1958dcb02 · Passage 5ce77cadc381b0de543e4f8f2c973bfbdaec9c577c78524ea86a0099c022049e · Zeichen 1724–2602 im Abschnitt